soul trial oral semaglutide cardiovascular outcomes trial results Researchers to present CV findings from of in high-risk type 2 diabetes soul trial oral semaglutide cardiovascular

Morning injection aligns peak appetite suppression with afternoon and evening hours when overeating is most common

Consult your provider if you experience severe or persistent nausea and vomiting that prevents adequate food or fluid intake, signs of pancreatitis including severe abdominal pain , vision changes or signs of diabetic retinopathy progression if you have diabetes, severe constipation lasting more than a week despite interventions, rapid heart rate or chest pain, or complete lack of appetite suppression or weight loss after reaching 1mg dose for at least four weeks

The one that works for you

Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study